Skip to content

Effect of Rasanjan in Obesity

Clinical Evaluation of Rasanjan in the management of Sthaulya (Obesity)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014198
Enrollment
48
Registered
2018-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Rasanjan diet and exercise: Rasanjan Capsules orally BD Dose- 2 gms/day with warm water. Total Duration 60 days Control Intervention1: Diet and exercise: Diet and exercise sheet, monito

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of either sex aged between 18 and 65 years. 2) BMI >= 30kg/m2 and 3) Willing and able to participate in the study for 60 days.

Exclusion criteria

Exclusion criteria: 1. Patients with known history of Pathophysiologic /genetic syndromes associated with obesity (Cushingâ??s syndrome, turnerâ??s syndrome) 2. Patients with known evidence of malignancy. 3. Patients on prolonged medication with corticosteroids, antidepressants, anticholinergics etc or any other drugs that may have an influence on the outcome of the study. 4. Patients with known history of major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, tuberculosis, Psycho- Neuro endocrine disorders etc) 5. Patients who have a past history of atrial fibrillation, Acute coronary syndrome, Myocardial infarction, stroke or severe arrhythmia in the last 6 months. 6. Patients with known history of serious hepatic and pulmonary disorders. 7. Known cases of Alcoholics and drug abusers. 8. Prior surgical therapy for obesity. 9. H/o Hypersensitivity to any of the trial drugs or their ingredients. 10. Pregnant or lactating women. 11. Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous 6 months. 12. Patients who have completed participation in any other clinical trial during the past six months. 13. Any other condition which the principal investigator thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
1 Change in 5% of weight OR 2 Change in BMI by 1 point OR 3 Change in inches loss minimum 2 inches Timepoint: 1st follow up 15 days 2nd follow up 30 days 3rd follow up 45 days 4th follow up 60 days

Secondary

MeasureTime frame
Change in 10% of weightTimepoint: 60 days

Countries

India

Contacts

Public ContactDr Mohan Ramchandra Joshi

Sanskrit Samhita Siddhant Department Tilak Ayurved Mahavidyalaya Pune

dr.manisha.singla@gmail.com8408902160

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026